Arena Completes Full Enrollment of Etrasimod Phase 2 ADVISE Trial for Atopic Dermatitis, Provides Program Updates
Go back to Arena Completes Full Enrollment of Etrasimod Phase 2 ADVISE Trial for Atopic Dermatitis, Provides Program Updates| Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) | Delayed: 99.98 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $99.98 | 52 Week High | $2.68 | |||
| Open | $0.14 | 52 Week Low | $1.30 | |||
| Day High | $99.98 | P/E | N/A | |||
| Day Low | $99.98 | EPS | $-0.08 | |||
| Volume | 21,430 | |||||
